EXPERT SYSTEMS CELEBRATES A MILESTONE WITH EILEAN THERAPEUTICS: INITIATION OF FIRST-IN-PATIENT TRIAL OF BALAMENIB, A SELECTIVE BEST-IN-CLASS MENIN INHIBITOR
Expert Systems, announces a significant milestone in partnership with Eilean Therapeutics LLC: the start of Phase 1 trial of balamenib (ZE63-0302), a highly selective inhibitor of the menin–KMT2A binding interaction, under the Clinical Trial Notification (CTN) scheme of the Australian Therapeutics Goods Administration (TGA).
EXPERT SYSTEMS EXPANDS PARTNERSHIP WITH EILEAN THERAPEUTICS AND JOINS ITS BEST-IN-CLASS PTPN2 INHIBITOR PROGRAM
Expert Systems announces the expansion of the collaboration with Eilean Therapeutics as it joins its new PTPN2 inhibitor program.
EXPERT SYSTEMS CELEBRATES COMPLETION OF SINGLE DOSE STUDIES AND START OF MULTIPLE HUMAN DOSING FOR LOMONITINIB, A SELECTIVE PAN-FLT3/IRAK4 INHIBITOR, ACHIEVED IN JUST 3 YEARS
Expert Systems announces a significant milestone in partnership with Eilean Therapeutics LLC: the successful completion of a single ascending dose Phase 1 clinical trial for lomonitinib, a selective pan-FLT3/IRAK4 inhibitor, alongside the launch of a multiple ascending dose Phase 1 study.
EXPERT SYSTEMS CELEBRATES ACCELERATED START OF HUMAN DOSING FOR EILETOCLAX, A SELECTIVE BCL2 INHIBITOR, ACHIEVED IN JUST 3 YEARS
Expert Systems proudly announces a significant achievement in collaboration with Eilean Therapeutics LLC: the commencement of first-in-human trials for eiletoclax, a highly potent BCL2 inhibitor, within just three years.
EXPERT SYSTEMS FACILITATES RAPID ADVANCEMENT OF GROUNDBREAKING COVID-19 TREATMENT, TRX01, TO CLINICAL TRIALS WITHIN TWO YEARS
Expert Systems Inc. announces the initiation of a first-in-human trial of TRX01 by their partner Trawsfynydd Therapeutics.